The healthcare provider will determine the regimen
Licensing (Marketing Authorisation): The MHRA has approved: Semaglutide (Wegovy) for adults with BMI 30 kg/m or BMI 27 kg/m with at least one weight-related comorbidity Liraglutide (Saxenda) with similar BMI criteria NHS Access (NICE Guidance): According to NICE guidance (TA664 for semaglutide), NHS-funded treatment is more restricted and typically available for adults with: BMI 35 kg/m with at least one weight-related comorbidity (such as hypertension, type 2 diabetes, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease) For individuals from Black, Asian, and minority ethnic backgrounds, lower BMI thresholds may apply, recognising that these populations face increased metabolic risk at lower BMI levels
Shipping is included in the price for patients using our Get Treated Privately service in England, and is free for NHS Quit Smoking Service orders
A subset of researchers also buy Ipamorelin spray specifically to compare metered-dose consistency against manually drawn injectable doses, since a pump mechanism removes some of the volumetric variability associated with syringe-based measurement at very small volumes
If the underlying issue is desire rather than blood flow, switching mechanisms makes clinical sense